Online citations, reference lists, and bibliographies.

Comparison Of 131I Whole-body Imaging, 131I SPECT/CT, And 18F-FDG PET/CT In The Detection Of Metastatic Thyroid Cancer

Jong-Ryool Oh, Byung-hyun Byun, Sun-pyo Hong, A. Chong, J. Kim, Su-Woong Yoo, Sae-Ryung Kang, Dongyeon Kim, Ho-Chun Song, H. Bom, J. Min
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PurposeThe aim of this study was to compare 131I whole-body scintigraphy (WBS), WBS with 131I single photon emission computed tomography/computed tomography (SPECT/CT), and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in the detection of distant metastases of differentiated thyroid cancer (DTC).MethodsA total of 140 patients with 258 foci of suspected distant metastases were evaluated. 131I WBS, 131I SPECT/CT, and 18F-FDG PET/CT images were interpreted separately. The final diagnosis was obtained from histopathologic study, serum thyroglobulin level, other imaging modalities, and/or clinical follow-up.ResultsOf the 140 patients with 258 foci, 46 patients with 166 foci were diagnosed as positive for distant metastasis. The sensitivity, specificity, and diagnostic accuracy of each imaging modality were 65, 55, and 59%, respectively, for 131I WBS; 65, 95, and 85% for 131I SPECT/CT, respectively; and 61, 98, and 86%, respectively, for 18F-FDG PET/CT in patient-based analyses. Lesion-based analyses demonstrated that both SPECT/CT and PET/CT were superior to WBS (p<0.001) in all patient groups. SPECT/CT was superior to WBS and PET/CT (p<0.001) in patients who received a single challenge of radioiodine therapy, whereas PET/CT was superior to WBS (p=0.005) and SPECT/CT (p=0.013) in patients who received multiple challenges.ConclusionBoth SPECT/CT and PET/CT demonstrated high diagnostic performance in detecting metastatic thyroid cancer. SPECT/CT was highly accurate in patients who underwent a single challenge of radioiodine therapy. In contrast, 18F-FDG PET/CT presented the highest diagnostic performance in patients who underwent multiple challenges of radioiodine therapy.
This paper references
Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables.
D. Casara (1993)
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
DS Cooper (2009)
10.1016/S0098-1672(08)79209-9
Recommendations on the Use of 18F-FDG PET in Oncology
A. Elster (2009)
10.1677/ERC-07-0229
Bone metastases from differentiated thyroid carcinoma.
M. Muresan (2008)
10.1007/s13139-010-0051-y
Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer
A. Chong (2010)
Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
U. Feine (1996)
10.1016/S0167-5877(00)00115-X
Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests.
M. Greiner (2000)
Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
J. Min (2001)
Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma.
T. Petrich (2002)
10.3322/canjclin.55.1.10
Cancer Statistics, 2005
A. Jemal (2005)
10.1148/radiology.148.3.6878708
A method of comparing the areas under receiver operating characteristic curves derived from the same cases.
J. Hanley (1983)
10.2967/jnumed.108.052399
Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma
L. Chen (2008)
10.1210/JCEM.86.4.7390
Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas.
M. Bernier (2001)
10.1089/thy.2009.0110
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
D. Cooper (2009)
Anaplastic carcinoma following well-differentiated thyroid cancer: etiological considerations.
D. Kapp (1982)
10.1530/EJE-07-0903
The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
A. Alzahrani (2008)
FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
N. Alnafisi (2000)
10.1210/JC.2005-1534
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
R. Robbins (2006)
10.4081/AR.2010.E1
Trends in hospitalization for fall-related injury among older adults in the United States, 1988-2005.
C. Orces (2009)
Increasing incidence of differentiated thyroid
AY Chen
10.1053/J.SEMNUCLMED.2006.03.002
Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
P. Lind (2006)
10.1097/00006231-200306000-00015
The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings.
M. Carlisle (2003)
10.2967/jnumed.108.056572
131I SPECT/CT in the Follow-up of Differentiated Thyroid Carcinoma: Incremental Value Versus Planar Imaging
A. Spanu (2009)
10.1007/s00259-008-1044-2
Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen
S. Kohlfuerst (2008)
Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
F. Moog (2000)
Lung metastases from differentiated thyroid carcinoma. A 40 years' experience.
G. Ronga (2004)
10.1089/THY.2000.10.261
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients.
A. Pittas (2000)
10.1089/THY.2006.16.109
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
D. Cooper (2006)
10.1002/cncr.24416
Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005
A. Chen (2009)
Revised American
DS Cooper
10.1016/j.clinimag.2008.06.024
The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer.
H. Wang (2009)
18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
A. Shammas (2007)
10.2967/jnumed.108.052746
Impact of 131I SPECT/Spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation
D. Schmidt (2009)
Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
B. Schlüter (2001)
Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer
M Greiner (2009)



This paper is referenced by
10.1016/J.RADI.2012.05.004
Analysis of CT acquisition parameters suitable for use in SPECT/CT: A free-response receiver operating characteristic study
J. D. Thompson (2012)
10.1007/978-3-319-54493-9_19
Imaging Modalities in the Diagnosis of Recurrent or Metastatic Thyroid Cancer
Jorge D. Oldan (2017)
10.1007/978-3-642-35283-6_4
SPECT/CT for Thyroid Cancer Imaging
A. Avram (2014)
10.1177/0284185114564438
Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases
C. Chang (2016)
10.3109/07853890.2014.923739
Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer
Hetal H Patel (2014)
10.1007/978-1-4939-3314-3_14
The Utility of SPECT-CT in Differentiated Thyroid Cancer
K. Kulkarni (2016)
10.1007/s40336-013-0024-0
131I whole-body scan or 18FDG PET/CT for patients with elevated thyroglobulin and negative ultrasound?
G. Treglia (2013)
10.2967/jnumed.119.240945
Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer
K. Donohoe (2020)
10.1007/978-3-319-20523-6_15
Imaging for Preoperative Assessment and Staging of Thyroid Cancer
James X. Wu (2016)
10.1097/MNM.0000000000000657
Prognostic value of preoperative 18F-FDG PET/CT in papillary thyroid cancer patients with a high metastatic lymph node ratio: a multicenter retrospective cohort study
S. Kwon (2017)
10.1007/s40618-020-01374-7
Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues
A. Nervo (2020)
10.1097/MNM.0b013e328358d9c0
Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer
Zhong-ling Qiu (2012)
10.3950/JIBIINKOKA.117.673
[Impact of 131I SPECT/CT on the management of differentiated thyroid carcinoma outpatients with radioablation].
Daisuke Mizokami (2014)
10.1007/s00259-019-04404-6
Two decades of SPECT/CT – the coming of age of a technology: An updated review of literature evidence
O. Israel (2019)
10.1007/s00256-013-1714-4
Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma
B. H. Byun (2013)
10.4329/wjr.v8.i6.635
Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.
Ka-Kit Wong (2016)
10.1097/MNM.0b013e3283550257
Role of SPECT/CT in differentiated thyroid cancer
T. Barwick (2012)
10.1210/er.2013-1030
Endocrine scintigraphy with hybrid SPECT/CT.
K. K. Wong (2014)
10.1159/000481707
Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis
Friederike Schütz (2017)
10.3413/Nukmed-0541-12-11
Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake.
C. Hong (2013)
10.1177/0284185115594645
F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
T. Haslerud (2016)
10.1097/RLU.0b013e318286b9bb
Usefulness of SPECT/CT for equivocal findings on (131)I whole-body scan in a patient with differentiated papillary thyroid cancer.
Byungwook Choi (2014)
10.2967/jnumed.112.105049
Performance of Whole-Body PET/CT for the Detection of Distant Malignancies in Various Cancers: A Systematic Review and Meta-Analysis
G. Xu (2012)
10.9734/BJMMR/2013/3312
Axillary Lymph Node Metastasis from Thyroid Malignancy: Unusual Presentation with Ominous Implications
Norman Oneil Machado (2013)
10.5772/25514
Physiologic and False Positive Pathologic Uptakes on Radioiodine Whole Body Scan
Byeong-Cheol Ahn (2011)
10.1007/s00259-012-2331-5
124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT
C. D. Pont (2012)
10.5772/26287
Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer
Ho-Chun Song (2011)
10.1177/0194599811423007
18F-fluorodeoxyglucose and 131I Radioguided Surgical Management of Thyroid Cancer
Carrie L. Francis (2012)
10.1186/s12880-015-0047-2
A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and 99mTc-MDP whole-body bone scanning for imaging osteolytic bone metastases
Lin Zhang (2015)
I SPECT/CT in the Follow-Up of Patients With Differentiated Thyroid Carcinoma
Mareen Menges (2012)
False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer.
Jong-Ryool Oh (2012)
10.3413/nukmed-0489-12-03
Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.
Burkhard Riemann (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar